Page 1 | Search Results | Cancer Research | American Association for Cancer Research

1-20 of 22

Sort by

Sort Order Select

Journal Articles

Abstract A021: Evolutionary immunotherapy in NSCLC: An integrated approach

Sandhya Prabhakaran, Taylor M. Bursell, Kimberly Luddy, Julian Pineiro, Rafael Bravo, Jeffrey West, Megan Johnson, Mark Robertson-Tessi, Amer A. Beg, Jhanelle E. Gray, Scott Antonia, Robert A. Gatenby, Alexander R. A. Anderson

Cancer Res (2024) 84 (3_Supplement_2): A021.

https://doi.org/10.1158/1538-7445.CANEVOL23-A021

Published: 01 February 2024

View article titled, Abstract A021: Evolutionary immunotherapy in NSCLC: An integrated approach

Journal Articles

Abstract 853: The impact of normal tissue density on tumor growth and evolution in a 3D whole-tumor model of lung cancer

Rafael Ramon Bravo, Mark Robertson-Tessi, Alexander R. Anderson, Robert Gatenby, Scott Antonia, Jhanelle Gray, Amer Beg, Matthew Schabath

Cancer Res (2023) 83 (7_Supplement): 853.

https://doi.org/10.1158/1538-7445.AM2023-853

Published: 04 April 2023

View article titled, Abstract 853: The impact of normal tissue density on tumor growth and evolution in a 3D whole-tumor model of lung cancer

Journal Articles

Abstract 3193: Developing non-exhausted tumor infiltrating lymphocytes (TILs) as a therapy for glioblastoma

Kelly M. Hotchkiss, Pamela Noldner, Kirit Singh, Anoop Patel, Peter Fecci, Scott Antonia, Beth H. Shaz, Mustafa Khasraw

Cancer Res (2023) 83 (7_Supplement): 3193.

https://doi.org/10.1158/1538-7445.AM2023-3193

Published: 04 April 2023

View article titled, Abstract 3193: Developing non-exhausted tumor infiltrating lymphocytes (TILs) as a therapy for glioblastoma

Journal Articles

Abstract 124: Autocrine signaling extends PD-L1 expression in NSCLC following an active immune response

Taylor M. Bursell, Sandhya Prabhakaran, Kimberly Luddy, Julian Pineriro, Rafael Bravo, Jeffrey West, Mark Robertson-Tessi, Aner Beg, Jhanelle Gray, Scott Antonia, Robert Gatenby, Alexander Anderson

Cancer Res (2023) 83 (7_Supplement): 124.

https://doi.org/10.1158/1538-7445.AM2023-124

Published: 04 April 2023

View article titled, Abstract 124: Autocrine signaling extends PD-L1 expression in NSCLC following an active immune response

Journal Articles

Abstract 5037: Distinct tumor-immune ecologies in NSCLC patients predict progression and define a clinical biomarker of therapy response

Sandhya Prabhakaran, Chandler Gatenbee, Mark Robertson-Tessi, Amer A. Beg, Jhanelle Gray, Scott Antonia, Robert A. Gatenby, Alexander R. Anderson

Cancer Res (2022) 82 (12_Supplement): 5037.

https://doi.org/10.1158/1538-7445.AM2022-5037

Published: 15 June 2022

View article titled, Abstract 5037: Distinct tumor-immune ecologies in NSCLC patients predict progression and define a clinical biomarker of therapy response

Journal Articles

Abstract 3542: Oncolytic adenovirus encoding transgenes for IFN-beta and recombinant CD40 ligand promotes conventional dendritic cell activation and trafficking with enhanced tumor infiltrating lymphocytes for effective cancer immunotherapy

Hong Zheng, Scott Antonia, Mark J. Cantwell, Xiaoqing Yu, Amer A. Beg

Cancer Res (2022) 82 (12_Supplement): 3542.

https://doi.org/10.1158/1538-7445.AM2022-3542

Published: 15 June 2022

View article titled, Abstract 3542: Oncolytic adenovirus encoding transgenes for IFN-beta and recombinant CD40 ligand promotes conventional dendritic cell activation and trafficking with enhanced tumor infiltrating lymphocytes for effective cancer immunotherapy

Journal Articles

Abstract B020: Distinct spatiotemporal tumor-immune ecologies enable disease prediction in NSCLC patients

Sandhya Prabhakaran, Chandler Gatenbee, Mark Robertson-Tessi, Amer A. Beg, Jhanelle Gray, Scott Antonia, Robert A. Gatenby, Alexander R.A. Anderson

Cancer Res (2022) 82 (10_Supplement): B020.

https://doi.org/10.1158/1538-7445.EVODYN22-B020

Published: 15 May 2022

View article titled, Abstract B020: Distinct spatiotemporal tumor-immune ecologies enable disease prediction in NSCLC patients

Journal Articles

Abstract 697: Defining anti-tumor immune stimulatory mechanisms of MEM-288, a CD40 ligand and IFN-beta dual-transgene armed oncolytic adenovirus

Hong Zheng, Chase D. Powell, Scott Antonia, Mark J. Cantwell, Bradford A. Perez, Amer A. Beg

Cancer Res (2021) 81 (13_Supplement): 697.

https://doi.org/10.1158/1538-7445.AM2021-697

Published: 01 July 2021

View article titled, Abstract 697: Defining anti-tumor immune stimulatory mechanisms of MEM-288, a CD40 ligand and IFN-beta dual-transgene armed oncolytic adenovirus

Journal Articles

Abstract CT056: Durable complete responses to adoptive cell transfer using tumor infiltrating lymphocytes (TIL) in non-small cell lung cancer (NSCLC): A phase I trial

Cancer Res (2020) 80 (16_Supplement): CT056.

https://doi.org/10.1158/1538-7445.AM2020-CT056

Published: 15 August 2020

View article titled, Abstract CT056: Durable complete responses to adoptive cell transfer using tumor infiltrating lymphocytes (TIL) in non-small cell lung cancer (NSCLC): A phase I trial

Journal Articles

Abstract 4578: Development of MEM-288, a dual-transgene armed and conditionally replication-enhanced oncolytic adenovirus with potent systemic antitumor immunity

Hong Zheng, Wenjie Dai, Scott Antonia, Mark J. Cantwell, Amer A. Beg

Cancer Res (2020) 80 (16_Supplement): 4578.

https://doi.org/10.1158/1538-7445.AM2020-4578

Published: 15 August 2020

View article titled, Abstract 4578: Development of MEM-288, a dual-transgene armed and conditionally replication-enhanced oncolytic adenovirus with potent systemic antitumor immunity

Journal Articles

Abstract CT031: Updated efficacy and safety profile of durvalumab monotherapy in urothelial carcinoma

Cancer Res (2018) 78 (13_Supplement): CT031.

https://doi.org/10.1158/1538-7445.AM2018-CT031

Published: 01 July 2018

View article titled, Abstract CT031: Updated efficacy and safety profile of durvalumab monotherapy in urothelial carcinoma

Journal Articles

Abstract CT113: Safety and activity of second-line durvalumab + tremelimumab in non-squamous advanced NSCLC

Jamie Chaft, Byoung Chul Cho, Myung-Ju Ahn, Sylvestre Le Moulec, Eun Kyung Cho, Vassiliki Papadimitrakopoulou, Edward Garon, Sylvia Lee, Santiago Ponce Aix, Patrick C. Ma, Gregory Otterson, Rajesh Narwal, Guozhi Gao, Jennifer McDevitt, Judson Englert, Scott Antonia

Cancer Res (2018) 78 (13_Supplement): CT113.

https://doi.org/10.1158/1538-7445.AM2018-CT113

Published: 01 July 2018

View article titled, Abstract CT113: Safety and activity of second-line durvalumab + tremelimumab in non-squamous advanced NSCLC

Journal Articles

Abstract CT077: Five-year follow-up from the CA209-003 study of nivolumab in previously treated advanced non-small cell lung cancer (NSCLC): Clinical characteristics of long-term survivors

Julie Brahmer, Leora Horn, David Jackman, David Spigel, Scott Antonia, Matthew Hellmann, John Powderly, Rebecca Heist, Lecia Sequist, David C. Smith, Philip Leming, William J. Geese, Dennis Yoon, Ang Li, Scott Gettinger

Cancer Res (2017) 77 (13_Supplement): CT077.

https://doi.org/10.1158/1538-7445.AM2017-CT077

Published: 01 July 2017

View article titled, Abstract CT077: Five-year follow-up from the CA209-003 study of nivolumab in previously treated advanced non-small cell lung cancer (NSCLC): Clinical characteristics of long-term survivors

Journal Articles

Abstract CT060: Efficacy, safety and tolerability of dasatinib combined with afatinib: a phase I trial in patients with epidermal growth factor receptor mutant (EGFRm) advanced non-small-cell lung cancer (NSCLC) after acquired tyrosine kinase inhibitor (TKI) resistance

Ben Creelan, Jhanelle Gray, Diana Lima, Scott Antonia, Alberto Chiappori, Tawee Tanvetyanon, Rebecca DeVane, Charles Williams, Eric Haura

Cancer Res (2016) 76 (14_Supplement): CT060.

https://doi.org/10.1158/1538-7445.AM2016-CT060

Published: 15 July 2016

View article titled, Abstract CT060: Efficacy, safety and tolerability of dasatinib combined with afatinib: a phase I trial in patients with epidermal growth factor receptor mutant (EGFRm) advanced non-small-cell lung cancer (NSCLC) after acquired tyrosine kinase inhibitor (TKI) resistance

Journal Articles

Abstract 274: Bavituximab modulates tumor microenvironment and activates CD8+ tumor infiltrating lymphocytes in a patient-derived 3D ex vivo system of lung cancer

Soner Altiok, Melanie Mediavilla-Valera, Jenny Kreahling, David Noyes, Tiffany N. Razabdouski, Nikoletta L. Kallinteris, Joseph Shan, Scott Antonia

Cancer Res (2015) 75 (15_Supplement): 274.

https://doi.org/10.1158/1538-7445.AM2015-274

Published: 01 August 2015

View article titled, Abstract 274: Bavituximab modulates tumor microenvironment and activates CD8+ tumor infiltrating lymphocytes in a patient-derived 3D ex vivo system of lung cancer

Journal Articles

Abstract 1704: Combination of Pirfenidone and Cisplatin as a potential therapeutic strategy in NSCLC

Melanie Mediavilla-Varela, David Noyes, Kingsley Boateng, Scott Antonia

Cancer Res (2014) 74 (19_Supplement): 1704.

https://doi.org/10.1158/1538-7445.AM2014-1704

Published: 01 October 2014

View article titled, Abstract 1704: Combination of Pirfenidone and Cisplatin as a potential therapeutic strategy in NSCLC

Journal Articles

Abstract 4948: Pirfenidone as a potential therapeutic treatment for CAFs and cancer cells in NSCLC.

Melanie Mediavilla-Varela, Kimberly Luddy, David Noyes, Kingsley Boateng, Scott Antonia

Cancer Res (2013) 73 (8_Supplement): 4948.

https://doi.org/10.1158/1538-7445.AM2013-4948

Published: 15 April 2013

View article titled, Abstract 4948: Pirfenidone as a potential therapeutic treatment for CAFs and cancer cells in NSCLC.

Journal Articles

Phase II trial using the DNA synthesis and damage repair genes RRM1 and ERCC1 for chemotherapy selection in advanced non-small-cell lung cancer (NSCLC)

Gerold Bepler, Charles Williams, Alberto Chiappori, Eric Haura, Tawee Tanvetyanon, Scott Antonia, George Simon

Cancer Res (2007) 67 (9_Supplement): LB-358.

Published: 01 May 2007

View article titled, Phase II trial using the DNA synthesis and damage repair genes RRM1 and ERCC1 for chemotherapy selection in advanced non-small-cell lung cancer (NSCLC)

Journal Articles

All-trans-Retinoic Acid Improves Differentiation of Myeloid Cells and Immune Response in Cancer Patients

Noweeda Mirza, Mayer Fishman, Ingo Fricke, Mary Dunn, Anthony M. Neuger, Timothy J. Frost, Richard M. Lush, Scott Antonia, Dmitry I. Gabrilovich

Cancer Res (2006) 66 (18): 9299–9307.

https://doi.org/10.1158/0008-5472.CAN-06-1690

Published: 18 September 2006

View article titled, All-trans-Retinoic Acid Improves Differentiation of Myeloid Cells and Immune Response in Cancer Patients

Journal Articles

Effect of all-trans retinoic acid (ATRA) on differentiation of dendritic and immature myeloid cells in cancer patients

Dmitry I. Gabrilovich, Noweeda Mirza, Ingo Fricke, Nickolas Williams, Scott Antonia, Mayer Fishman

Cancer Res (2006) 66 (8_Supplement): 1146.

Published: 15 April 2006

View article titled, Effect of all-trans retinoic acid (ATRA) on differentiation of dendritic and immature myeloid cells in cancer patients

NARROW

Abstract A021: Evolutionary immunotherapy in NSCLC: An integrated approach

Abstract 853: The impact of normal tissue density on tumor growth and evolution in a 3D whole-tumor model of lung cancer

Abstract 3193: Developing non-exhausted tumor infiltrating lymphocytes (TILs) as a therapy for glioblastoma

Abstract 124: Autocrine signaling extends PD-L1 expression in NSCLC following an active immune response

Abstract 5037: Distinct tumor-immune ecologies in NSCLC patients predict progression and define a clinical biomarker of therapy response

Abstract 3542: Oncolytic adenovirus encoding transgenes for IFN-beta and recombinant CD40 ligand promotes conventional dendritic cell activation and trafficking with enhanced tumor infiltrating lymphocytes for effective cancer immunotherapy

Abstract B020: Distinct spatiotemporal tumor-immune ecologies enable disease prediction in NSCLC patients

Abstract 697: Defining anti-tumor immune stimulatory mechanisms of MEM-288, a CD40 ligand and IFN-beta dual-transgene armed oncolytic adenovirus

Abstract CT056: Durable complete responses to adoptive cell transfer using tumor infiltrating lymphocytes (TIL) in non-small cell lung cancer (NSCLC): A phase I trial

Abstract 4578: Development of MEM-288, a dual-transgene armed and conditionally replication-enhanced oncolytic adenovirus with potent systemic antitumor immunity

Abstract CT031: Updated efficacy and safety profile of durvalumab monotherapy in urothelial carcinoma

Abstract CT113: Safety and activity of second-line durvalumab + tremelimumab in non-squamous advanced NSCLC

Abstract CT077: Five-year follow-up from the CA209-003 study of nivolumab in previously treated advanced non-small cell lung cancer (NSCLC): Clinical characteristics of long-term survivors

Abstract CT060: Efficacy, safety and tolerability of dasatinib combined with afatinib: a phase I trial in patients with epidermal growth factor receptor mutant (EGFRm) advanced non-small-cell lung cancer (NSCLC) after acquired tyrosine kinase inhibitor (TKI) resistance

Abstract 274: Bavituximab modulates tumor microenvironment and activates CD8+ tumor infiltrating lymphocytes in a patient-derived 3D ex vivo system of lung cancer

Abstract 1704: Combination of Pirfenidone and Cisplatin as a potential therapeutic strategy in NSCLC

Abstract 4948: Pirfenidone as a potential therapeutic treatment for CAFs and cancer cells in NSCLC.

Phase II trial using the DNA synthesis and damage repair genes RRM1 and ERCC1 for chemotherapy selection in advanced non-small-cell lung cancer (NSCLC)

All-trans-Retinoic Acid Improves Differentiation of Myeloid Cells and Immune Response in Cancer Patients

Effect of all-trans retinoic acid (ATRA) on differentiation of dendritic and immature myeloid cells in cancer patients

Email alerts

AACR Journals

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only